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Abstract
Background: Bipolar disorder has been linked to alterations in the multifunctional enzyme glycogen synthase
kinase-3β (GSK3β). The mood stabilizer lithium inhibits GSK3β in vitro and in mouse brain, and this is
currently the strongest known potential therapeutic target of lithium. We tested whether lithium modified
GSK3β in vivo or in vitro in peripheral blood mononuclear cells (PBMCs) from healthy control and bipolar
disorder subjects.
Methods: The PBMCs were obtained from 23 healthy control subjects, 9 bipolar subjects currently treated
with lithium, and 13 lithium-free bipolar subjects. Immunoblot analyses were used to measure the inhibited,
serine9-phosphorylated GSK3β.
Results: The level of phospho-Ser9-GSK3β in PBMCs was regulated by agents that modified kinases and
phosphatases acting on GSK3β and was increased by in vitro lithium treatment. More important, phospho-
Ser9-GSK3β levels were eightfold higher in PBMCs from lithium-treated bipolar than healthy control
subjects.
Conclusions: Signaling pathways regulating serine9-phosphorylation of GSK3β can be studied in human
PBMCs. Both in vitro and in vivo therapeutic lithium treatment is associated with a large increase in phospho-
Ser9-GSK3β in PBMCs. Therefore, the inhibitory serine9-phosphorylation of GSK3β in human PBMCs may
provide a biochemical marker to evaluate the association between GSK3β inhibition and therapeutic
responses to lithium treatment.
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Abstract
Background—Bipolar disorder has been linked to alterations in the multifunctional enzyme
glycogen synthase kinase-3β (GSK3β). The mood stabilizer lithium inhibits GSK3β in vitro and in
mouse brain, and this is currently the strongest known potential therapeutic target of lithium. We
tested whether lithium modified GSK3β in vivo or in vitro in peripheral blood mononuclear cells
(PBMCs) from healthy control and bipolar disorder subjects.
Methods—The PBMCs were obtained from 23 healthy control subjects, 9 bipolar subjects
currently treated with lithium, and 13 lithium-free bipolar subjects. Immunoblot analyses were
used to measure the inhibited, serine9-phosphorylated GSK3β.
Results—The level of phospho-Ser9-GSK3β in PBMCs was regulated by agents that modified
kinases and phosphatases acting on GSK3β and was increased by in vitro lithium treatment. More
important, phospho-Ser9-GSK3β levels were eightfold higher in PBMCs from lithium-treated
bipolar than healthy control subjects.
Conclusions—Signaling pathways regulating serine9-phosphorylation of GSK3β can be studied
in human PBMCs. Both in vitro and in vivo therapeutic lithium treatment is associated with a
large increase in phospho-Ser9-GSK3β in PBMCs. Therefore, the inhibitory serine9-
phosphorylation of GSK3β in human PBMCs may provide a biochemical marker to evaluate the
association between GSK3β inhibition and therapeutic responses to lithium treatment.
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Much recent evidence indicates that the multifunctional enzyme glycogen synthase
kinase-3β (GSK3β) plays crucial roles in the etiology and treatment of mood disorders and
schizophrenia (Jope and Roh, in press). This connection was first established by the finding
that the mood stabilizer lithium directly inhibits GSK3β (Klein and Melton 1996). GSK3β is
an especially interesting target because many signaling pathways converge on GSK3β, and
GSK3β itself influences a broad spectrum of cellular functions. Among the nearly 50
substrates that are phosphorylated by GSK3β are proteins involved in regulating gene
expression, neuronal structure, and cell survival (Jope and Johnson 2004). These
multifaceted effects of GSK3β reveal that it is a central regulator of neural plasticity that
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may be a key process in susceptibility, onset, therapeutic responses, or a combination of
these factors in mood disorders and schizophrenia (Duman et al 2000; Nestler et al 2002).
Lithium has dual effects that work in combination to inhibit GSK3β in vivo. First, lithium
binds directly to GSK3β to inhibit its activity, with 2 mmol/L lithium providing
approximately 50% inhibition of GSK3β activity (Klein and Melton 1996; Stambolic et al
1996). This relatively high concentration of lithium compared with its therapeutically
effective concentration of approximately 1 mmol/L initially suggested that in vivo
concentrations of lithium achieved in treated patients may only moderately inhibit the
activity of GSK3β; however, the direct inhibitory effect of lithium is amplified in vivo by a
second mechanism involving phosphorylation of GSK3β. The activity of GSK3β is
principally regulated by phosphorylation of a regulatory serine-9 in its N-terminal region.
Phosphorylation of this serine is the major physiologic mechanism that inhibits the activity
of GSK3β in cells (Stambolic and Woodgett 1994; Sutherland et al 1993). Thus, the
likelihood that lithium significantly inhibits GSK3β in vivo was bolstered by the finding that
a therapeutically relevant level of lithium greatly increases the serine9-phosphorylation of
GSK3β in mouse brain in vivo (De Sarno et al 2002). This finding revealed that the direct
modest inhibition of GSK3β by lithium was amplified in vivo by the serine9-
phosphorylation of GSK3β, allowing lithium at therapeutic concentrations to provide a more
robust inhibition of GSK3β than could be achieved solely by its direct inhibition of the
enzyme (Jope 2003).
Because lithium-induced serine9-phosphorylation of GSK3β may be a key factor in allowing
a therapeutically relevant concentration of lithium to substantially inhibit the activity of
GSK3β, it is important to determine whether lithium causes this modification in cells from
healthy and bipolar human subjects. Unfortunately, this cannot be addressed using
postmortem human brain samples because GSK3β is rapidly dephosphorylated following
death (Li et al 2005). Therefore, in this study we examined whether in vitro and therapeutic
in vivo lithium treatment increased the serine9-phosphorylation of GSK3β in human
peripheral blood mononuclear cells (PBMCs). The results show that lithium robustly
increases this inhibitory modification of GSK3β in human PBMCs, further supporting the
likelihood that lithium substantially inhibits GSK3β in human brain and that this may be an
important therapeutic target of lithium.
Methods and Materials
Subjects and Procedures
The study was conducted in the Department of Psychiatry and Behavioral Neurobiology at
the University of Alabama at Birmingham Center for Psychiatric Medicine. The study was
approved by the University of Alabama at Birmingham Institutional Review Board, and
written informed consent was obtained from all subjects after receiving a complete
description of the study.
Men and women aged 19–65 years with a primary diagnosis of bipolar disorder (BD)
according to DSM-IV criteria were recruited from the psychiatric outpatient clinic or the
Center for Psychiatric Medicine in-patient hospital at the University of Alabama at
Birmingham. Subjects were excluded if they concomitantly met criteria for any other major
DSM-IV Axis I diagnosis, such as psychotic disorder, major depressive disorder, anxiety
disorder, or alcohol or other substance dependence. At the initial screening, eligible subjects
may have been taking any psychotropics for bipolar disorder, such as lithium,
anticonvulsants, antipsychotics, antidepressants, or anxiolytics. If they were taking lithium,
the length of lithium treatment must have been at least 4 weeks. The pharmacologic
treatment was the decision of the primary physician and was not influenced in any way by
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this study. A total of 22 bipolar subjects were enrolled in the study, among which 9 were
taking lithium with an average serum level of .87 ± .18 mEq/L at the time of blood
collection; the other 13 were either medication-free (n = 3) or taking any psychotropic
except lithium for bipolar disorder. In addition, 23 healthy control subjects who had no
history of psychiatric illnesses or any major medical illness were enrolled in the study.
These control subjects were medication-free at the time of blood collection. Demographic
characteristics of the subjects are shown in Table 1.
Psychiatric and medical histories along with vital signs, a physical examination, and a
neurologic examination, were obtained before blood collection. Serum levels of lithium,
valproate, or carbamazepine were measured if subjects were taking one of these mood
stabilizers. The most recent (within 1 week) laboratory data on fluid balance, blood glucose,
CBC with differential, thyroid function, and liver function were reviewed to ensure that
these parameters were within the normal range. Clinical symptoms of BD were assessed
using the Young Mania Rating Scale (YMRS), the Hamilton Depression Rating Scale
(HAM-D), and the Clinical Global Impression of Severity (CGI-S) scale. All the
assessments were completed within 3 days of blood collection.
PBMC Preparation, In Vitro Treatments, and GSK3β Measurements
Approximately 50 mL of blood from each subject was collected by venipuncture into
heparin-containing vacutainers. Whole blood from each subject was diluted with
RPMI-1640 cell culture media (Cellgro, Herndon, Virginia). The PBMCs were extracted
from whole blood by addition of .25 volume of IsoPrep solution (Robbins Scientific,
Sunnyvale, California) into the bottom of the blood-containing tube followed by
centrifugation (2000 rpm for 20 min at room temperature). The cell layer containing PBMCs
was transferred to a clean tube and was washed with RPMI-1640 media twice.
Approximately 5 × 107 PBMCs were obtained from 50 mL of whole blood. Aliquots of
PBMCs (3 × 106 cells) were placed into individual microfuge tubes or 24-well cell culture
dishes. One aliquot of PBMCs was immediately lysed in lysis buffer (10 mmol/L Tris-HCl,
pH 7.4, 150 mmol/L NaCl, 1 mmol/L ethylenediamine tetraacetate, 1 mmol/L ethylene
glycol bis-2-aminoethyl ether-N,N′,N″,n′-tet-raacetic acid, .5% NP-40, 10 μg/L leupeptin,
10 μg/L aprotinin, 5 μg/L pepstatin, .1 mmol/L β-glycerophosphate, 1 mmol/L
phenylmethanesulfonyl fluoride, 1 mmol/L sodium vanadate, and 100 nmol/L okadaic acid)
and centrifuged at 14,000 rpm for 10 min. The supernatant was incubated on ice for 2 hours
and then processed along with the in vitro–treated PBMC samples. In one group of
experiments, the PBMC samples were incubated for 2 hours in RPMI-1640 media at 37°C in
the absence or the presence of the indicated agents for the indicated times up to 1 hour. In
the second group of experiments, PBMC samples were preincubated for 1 hour in
RPMI-1640 media containing 10% Fetal Clone II (HyClone, Logan, Utah) at 37°C, followed
by the addition of lithium and a further incubation for 20 hours. Agents tested in these
experiments include lithium chloride, phenylarsine oxide (PAO; Sigma), phorbol 12-
myristate 13-acetate (PMA; Alexis, California), and calyculin A (Alamore Labs, Jerusalem,
Israel). After incubation, PBMCs were lysed with lysis buffer and centrifuged, and the
supernatants were collected. Protein concentrations were measured using the Bradford
protein assay (Bradford 1976).
For immunoblotting, proteins from PBMC lysates were mixed with Laemmli sample buffer
(2% sodium dodecyl sulfate [SDS]) and placed in a boiling water bath for 5 min. Proteins
(15 μg) were resolved in 10% SDS-polyacrylamide gels and transferred to nitrocellulose.
Blots were probed with antibodies to phospho-Ser9-GSK3β (Cell Signaling Technology,
Beverly, Massachusetts) and total GSK3β (Southern Biotech, Birmingham, Alabama).
Immunoblots were developed using horseradish peroxidase–conjugated goat antimouse or
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goat antirabbit immunoglobulin G, followed by detection with enhanced
chemiluminescence. Protein bands were quantitated with a densitometer.
Data Analysis
Data analyses were performed using Microsoft Excel (2003) and Sigma Stat (3.0). The
analyzed data set consisted of three groups of subjects: healthy control subjects, BD subjects
currently treated with lithium, and lithium-free BD subjects. The unpaired rank sum test for
two-group comparison was used to analyze differences between in vitro treatments and
between healthy control and BD subjects. Data from lithium-concentration response
experiments within each group of subjects were analyzed using one-way repeated measure
ANOVA on rank.
Results
We first tested whether the serine9-phosphorylation of GSK3β could be modulated in
human PBMCs. To do this, freshly isolated PBMCs from healthy control subjects were
incubated in vitro and then immunoblot analyses were carried out using a phosphorylation-
dependent antibody that specifically identifies GSK3β only when it is phosphorylated on its
regulatory residue, serine-9 (phospho-Ser9-GSK3β). This was compared with the total
amount of GSK3β, measured using an antibody that identifies all GSK3β to assess the
proportion of all the GSK3β in PBMCs that contained the inhibitory serine9-
phosphorylation modification. Cells were treated with several agents known to increase
phospho-Ser9-GSK3in other types of cells to test if phospho-Ser9-GSK3β levels
dynamically changed in PBMCs. PBMCs were incubated with a phorbol ester (PMA) to
activate protein kinase C, which is known to phosphorylate GSK3β in other cells (Goode et
al 1992; Tsujio et al 2000). Treatment with PMA caused a rapid increase in the serine9-
phosphorylation of GSK3β that was evident within 15 min of treatment, reached a peak after
60 min, and was maintained above the initial basal level for at least 2 hours during exposure
to PMA (Figure 1A and 1B). Furthermore, the PMA-induced increase in phospho-Ser9-
GSK3β was concentration-dependent with an EC50 of approximately 10 nmol/L PMA
(Figure 1C). Cells also were treated with two inhibitors of protein phosphatases; PAO was
used because it inhibits protein phosphotyrosine phosphatases. Phosphotyrosine residues are
commonly associated with activated growth factor receptors, which can stimulate
intracellular signaling cascades leading to serine9-phosphorylation of GSK3β, and thus PAO
may potentiate this signal to phospho-Ser9-GSK3β. Treatment with PAO (1 μmol/L) caused
time-dependent increases in the phosphorylation of GSK3β on serine-9 in human PBMCs,
with the increase lasting more than 90 min (Figure 1A and 1B). The effect of PAO was
concentration-dependent with an EC50 of approximately .2 μmol/L and a maximal effect at 1
μmol/L (Figure 1C). Additionally, calyculin A was used because it inhibits protein
phosphatases 1 and 2A (Millward et al 1999). In other types of cells protein phosphatases 1
and 2A are known to remove the phosphate from the serine-9 of GSK3β (Grimes and Jope
2001), If these protein phosphatases dynamically regulate phospho-Ser9-GSK3β in human
PBMCs, phosphatase inhibition by calyculin A should elevate phosphorylation levels. This
was found to be the case because treatment with calyculin A robustly increased the level of
phospho-Ser9-GSK3β time- and concentration-dependently (Figure 1). With all treatments
only minor changes in the total level of GSK3β were detected (Figure 1A), indicating that
the effects were primarily on the serine-9 phosphorylation, not expression, of GSK3β. These
results show that the serine9-phosphorylation of GSK3β is a dynamic process in human
PBMCs and is regulated by changing the activities of kinases and phosphatases in these
cells.
We next compared the basal levels of phospho-Ser9-GSK3β in human PBMCs from three
groups of subjects: healthy control subjects, lithium-treated BD subjects, and lithium-free
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BD subjects. The basal levels of phospho-Ser9-GSK3β from the three groups of subjects
clearly stratified into three distinct categories (Figure 2). The basal level of phospho-Ser9-
GSK3β was lowest in healthy control subjects, it was elevated about threefold in lithium-
free BD subjects, and it was highest (eightfold the level in healthy control subjects; p = .038
compared with healthy controls) in lithium-treated BD subjects. These findings are
consistent with the conclusion that therapeutic in vivo treatment with lithium increased the
serine9-phosphorylation of GSK3β in PBMCs as it did in mouse brain in vivo and in
cultured cells (reviewed by Jope 2003). The elevated serine9-phosphorylation of GSK3β in
PBMCs from both lithium-treated and lithium-free BD subjects was found to be reversible
because incubation of PBMCs in serum-free media for 2 hours caused the levels of phospho-
Ser9-GSK3β to revert to a low level that was similar to the basal levels in healthy control
subjects.
We also tested whether in vitro treatment with lithium was capable of increasing the serine9-
phosphorylation of GSK3β in PBMCs from each group of subjects. To test this, PBMCs
were incubated in serum-free media for 1 hour and then treated with a maximal
concentration of lithium (20 mmol/L) for a short period of time (1 hour) followed by
immunoblot analyses of phospho-Ser9-GSK3β (Figure 2). This high concentration of
lithium was used to attain maximal inhibition of GSK3β within a short treatment time. In
PBMCs from healthy control subjects, this in vitro lithium treatment caused a significant
fivefold increase (p = .002 compared with serum-free no treatment samples) in the level of
phospho-Ser9-GSK3β. In vitro lithium treatment of PBMCs from lithium-treated BD
subjects raised the level of phospho-Ser9-GSK3β to the high basal level found in these
subjects. The effect of in vitro lithium treatment of PBMCs from lithium-free BD subjects
also raised phospho-Ser9-GSK3β to a high level. The effect of in vitro lithium treatment in
BD subjects was statistically significant when compared with serum-free no treatment
samples, with p = .004 in lithium-treated BD subjects and p = .016 in lithium-free BD
subjects. Neither in vivo therapeutic lithium treatment nor in vitro lithium treatment changed
the level of total GSK3β in PBMCs (Figure 2A). Thus, these results show that in vivo
therapeutic lithium treatment was associated with elevated phospho-Ser9-GSK3β and that in
vitro lithium treatment also raised phospho-Ser9-GSK3β levels in human PBMCs.
Finally, we examined the concentration-dependence of the in vitro lithium-induced increases
in phospho-Ser9-GSK3β by incubating human PBMCs with lithium in a concentration range
of 1.25 to 10 mmol/L (Figure 3). In these experiments, the incubation time with lithium was
increased to 20 hours to allow detection of the effects of lower concentrations of lithium.
The levels of phospho-Ser9-GSK3β following in vitro lithium treatment were evaluated as a
percent of the basal level to take into account the different initial levels in each group of
subjects. These experiments showed that the phospho-Ser9-GSK3β in PBMCs from all three
groups of subjects significantly increased (p < .01) in a lithium concentration–dependent
manner within each group of subjects. The concentration-dependence of PBMCs was similar
among all three groups of subjects at the lower lithium concentration range (1.25–2.5 mmol/
L), with PBMCs from BD subjects tending to have greater responses than those from
healthy control subjects at the higher concentration range (5–10 mmol/ L). This prolonged in
vitro lithium treatment (20 hours) did not change the total level of GSK3β in PBMCs
(Figure 3A). Thus, even lower concentrations of lithium caused increases in phospho-Ser9-
GSK3β after human PBMCs were treated with lithium in vitro for a prolonged period of
time.
Discussion
Lithium inhibits GSK3β directly, and this inhibitory effect is amplified in mouse brain and
in cultured cells by an increase in the inhibitory serine9-phosphorylation of GSK3β (Jope
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2003). The lithium-induced increase in serine9-phosphorylation of GSK3β may be critical
because it provides a mechanism whereby a moderate direct inhibitory effect of lithium
achieved by therapeutically relevant lithium concentrations is amplified to achieve more
pronounced inhibition of GSK3β by the therapeutic level of lithium. Therefore, it was
important to determine whether this amplification mechanism is active in human cells. To
assess this, we tested whether serine9-phosphorylation of GSK3β was dynamically regulated
in human PBMCs and if in vivo therapeutic lithium administration as well as in vitro lithium
treatment of PBMCs was associated with increased levels of phospho-Ser9-GSK3β. The
results provide, for the first time, evidence that increases in phospho-Ser9-GSK3β are
associated with both in vivo and in vitro lithium treatment in PBMCs from BD subjects.
Our first goal was to assess the utility of using human PBMCs to study the regulation of
phospho-Ser9-GSK3β. Several signaling molecules or pathways were found to regulate the
serine9-phosphorylation of GSK3β in PBMCs. Treatment with PMA greatly increased
phospho-Ser9-GSK3β, showing that activation of protein kinase C can phosphorylate
GSK3β in PBMCs. Inhibition of protein phosphatases 1/2A with calyculin A also increased
phospho-Ser9-GSK3β, implicating these phosphatases in controlling the dephosphorylation
of GSK3β in PBMCs. Perhaps most interesting, the phosphotyrosine phosphatase inhibitor
PAO increased phospho-Ser9-GSK3β in PBMCs. This demonstrates the likelihood that
growth factor receptors activated by tyrosine phosphorylation stimulate signaling cascades,
leading to serine9-phosphorylation of GSK3β in PBMCs. Further studies are needed to
identify the specific growth factor receptors that are involved, such as neurotrophic factor
receptors (Besser and Wank 1999), because dysregulation of neurotrophic receptor signaling
pathways are known to be linked to mood disorders (Duman et al 2000). Overall, these in
vitro results demonstrate that the serine9-phosphorylation of GSK3β in human PBMCs is a
dynamic process and can be used to identify modulators of this inhibitory regulation of
GSK3β.
We found that in vitro and in vivo lithium treatment was associated with increased serine9-
phosphorylation of GSK3β, an effect matching changes previously reported in mouse brain
and continuous cultured cell lines (reviewed by Jope 2003). The mechanism through which
lithium increases phospho-Ser9-GSK3β in cells is not completely understood. Some data
indicate that lithium treatment causes activation of Akt, which leads to increased phospho-
Ser9-GSK3β (Chalecka-Franaszek and Chuang 1999), but this appears to be a cell-type
selective action. Other data indicate that as a result of lithium’s direct inhibition of GSK3β,
there is a secondary inhibition of the protein phosphatase responsible for dephosphorylating
GSK3β, which leads to greater serine9-phosphorylation of GSK3β (Zhang et al 2003). This
regulation allows for a phosphorylation-dependent amplification of the direct inhibitory
effect of lithium on GSK3β. Regardless of the mechanism, lithium clearly increased the
level of phospho-Ser9-GSK3β in human PBMCs. The most interesting finding was that the
level of phospho-Ser9-GSK3β was highly elevated in PBMCs from BD subjects currently
undergoing lithium therapy. This suggests that therapeutic lithium treatment causes
increased serine9-phosphorylation of GSK3β in human PBMCs. Taken in conjunction with
findings of the same effect of lithium in mouse brain (De Sarno et al 2002), these results
suggest that therapeutic levels of lithium are likely to increase the serine9-phosphorylation
of GSK3β in human brain. Unfortunately, this modification cannot be studied in postmortem
brain because there is a rapid loss of the phosphorylation during short postmortem intervals
(Li et al 2005). Nevertheless, these results suggest that the direct inhibitory effect of lithium
is amplified in humans by the increased inhibitory serine9-phosphorylation of GSK3β.
Recently increases in serotonergic activity and administration of the antidepressants
imipramine or fluoxetine were found to increase the serine9-phosphorylation of GSK3β in
mouse brain, suggesting that the deficient serotonergic activity that is associated with
depression may involve impaired inhibitory control of GSK3β (Li et al 2004). These
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findings suggest that if the increased phospho-Ser9-GSK3β caused by lithium treatment in
human PBMCs also occurs in human brain then lithium may be able to counteract this
deficiency associated with impaired serotonergic activity.
This study assessed the feasibility of examining the regulation of serine9-phosphorylation of
GSK3β in human PBMCs. This investigation is limited by the small sample size used in this
initial examination, as well as the mixed demographic characteristics of the subjects and the
presence of other psychotropic agents in many of the BD subjects. Additionally, PBMC
preparations contain a heterogeneous population of cells, which vary among individuals, a
factor that likely contributes to interindividual variations in the basal level of phospho-Ser9-
GSK3β. Our results indicate, however, that PBMCs are useful for examining both the in
vitro actions of drugs on GSK3β in human subjects and, more important, the in vivo
therapeutic effects of psychotropic agents. The increased phospho-Ser9-GSK3β levels
caused by lithium add support to the concept that GSK3β may be an important therapeutic
target of lithium, as well as other therapeutic agents. GSK3β is an interesting therapeutic
target because it is known to regulate neural plasticity in many ways through its
phosphorylation of numerous proteins involved in gene expression, neuronal remodeling,
and neuronal survival (Jope and Johnson 2004). Thus further studies of GSK3β
phosphorylation in human PBMCs should be useful for increasing our understanding of the
in vitro and in vivo actions of psychotropic agents in human subjects and to assess whether
the in vivo level of phospho-Ser9-GSK3β in PBMCs may serve as a biomarker related to
specific clinical symptoms or therapeutic response.
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Figure 1.
Increased phospho-Ser9-GSK3β in human peripheral blood mononuclear cells (PBMCs)
induced by activation of protein kinase C and phosphatase inhibitors. (A) Immunoblots of
phospho-Ser9-GSK3β (left panel) and total GSK3β (right panel) after PBMCs from healthy
control subjects were incubated at 37°C in serum-free media for 2 hours in the absence or
the presence of phorbol 12-myristate 13-acetate (PMA [1 μmol/L], phenylarsine oxide
[PAO; 1 μmol/L], or Calyculin A [.1 μmol/L] for the indicated times. (B) Quantitative
analysis of immunoblots showing the time-dependent increases of phospho-Ser9-GSK3β in
PBMCs after treatment with PMA, PAO, and calyculin A. (C) Quantitative analysis of
immunoblots showing the concentration-dependent increases of phospho-Ser9-GSK3β in
PBMCs after treatment with PMA, PAO, and calyculin A. The graphs in (B) and (C) show
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data from individual samples of PBMCs that demonstrate representative rates of change or
concentration-dependent responses typical of changes in PBMCs in response to these agents.
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Figure 2.
Phospho-Ser9-GSK3β in peripheral blood mononuclear cells (PBMCs) from healthy control
subjects and subjects with bipolar disorder (BD) before and after in vitro treatments. Freshly
isolated PBMCs from healthy control subjects (n = 13), BD subjects treated with lithium
(Lithium-Tx BD, n = 9), or BD subjects without lithium treatment (lithium-free BD, n = 13)
were (i) immediately lysed and incubated on ice for 2 hours (basal), (ii) incubated in serum-
free media for 2 hours (SF), or (iii) incubated in serum-free media for 1 hour followed by
incubation with 20 mmol/L lithium for 1 hour (LiCl). Phospho-Ser9-GSK3β and total
GSK3β in protein lysates (15 μg) from each subject were detected on the same immunoblot.
(A) Representative immunoblots from a healthy control subject, a lithium-treated BD
subject, and a lithium-free BD subject. (B) Immunoblots were analyzed by densitometry,
and values are calculated as the absolute optical density (OD) volume. Data shown are
average ± SEM. Statistical significance was calculated using an unpaired rank sum test for
two-group comparison. *p < .05 between basal phospho-Ser9-GSK3β of healthy control
subjects and lithium-treated BD subjects; **p < .05 between serum-free samples and in vitro
lithium-treated samples within each group of subjects.
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Figure 3.
Lithium concentration– dependent increase of phospho-Ser9-GSK3β in human peripheral
blood mononuclear cells (PBMCs). Freshly isolated cells were incubated in serum-
containing media for 1 hour followed by addition of lithium (0, 1.25, 2.5, 5, or 10 mmol/L)
and incubation for 20 hours. Phospho-Ser9-GSK3β and total GSK3β levels in PBMCs from
each subject were detected on the same immunoblot. (A) Representative immunoblots from
a healthy control subject. (B) Immunoblots were analyzed by densitometry, and values were
calculated as the percent of value obtained in PBMCs incubated in parallel without lithium
(0 mmol/L). Data shown are average values (n = 7–9) from healthy control subjects and
each bipolar group. In this set of experiments, only those samples that had treatments with
all five lithium concentrations are included for data analysis. Statistical significance was
calculated using one-way repeated-measures analysis of variance on rank for each lithium
concentration response within the same group of subjects. There is a significant (p < .01)
difference in the mean values among the lithium concentrations within each group of
subjects, and *p < .05 when the individual lithium concentration is compared with the
corresponding basal value (0 mmol/L).
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Table 1
Demographic and Clinical Summary
Lithium-Treated BD Lithium-Free BD Healthy Control
n 9 13 23
Age Range (years) 37–62 25–59 19–62
Gender
 F 4 10 11
 M 5 3 12
Race
 CA 6 10 12
 AA 3 3 5
 Others 0 0 6
Diagnosis
 BDI 5 8 N/A
 BDII 3 2 N/A
 BD NOS 1 3 N/A
Lithium treatment (> 4 wk) Serum level .87 ± .18 mEq/L No No
Other Psychotropics Valproate, lamotrigine, fluoxetine, venlafaxine, nortriptyline,
bupropion, ziprasidone, risperidone, aripiprazole, quetiapine, or
clonazepam
AA, African American; BD, bipolar disorder; BDI, bipolar disorder type I; BDII, bipolar disorder type II; BD NOS, bipolar disorder not otherwise
specified; CA, Caucasian; F, female; M, male; Others, any race other than CA or AA.
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